EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BCG vaccination elicits protection against M. tuberculosis infection mediated by two phases of T cell immunity

Abiola F Ogunsola, Rocky Lai, Kelly Cavallo, Anthony V Tran, Gillian L Beamer, Samuel M Behar

JCI Insight · 2026

DOI: 10.1172/jci.insight.201000 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCI Insight, 2026. Verfasst von Abiola F Ogunsola und 5 weiteren Autor:innen. Beteiligte Einrichtung: Morningside Graduate School of Biomedical Sciences. Hauptthemen laut MEDLINE: BCG Vaccine, Mycobacterium tuberculosis, Tuberculosis, T-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vaccine development for tuberculosis (TB) is a global priority. Our studies using Collaborative Cross (CC) mice show that genetic diversity influences the efficacy of BCG, the most widely used TB vaccine. BCG vaccination of CC042 mice reduced their lung bacillary burden and increased their survival following low-dose aerosol Mycobacterium tuberculosis infection (MTBI), despite impaired T cell trafficking due to a defective Itgal gene. BCG vaccination conferred early bacillary control that appeared to be independent of B cell or T cell recall responses following MTBI. In contrast, long-term survival of BCG-vaccinated CC042 mice after MTBI required T cells. Thus, CC042 mice reveal two phases of immunity induced by BCG: an early phase mediated by innate immunity or innate-like T cells and a later phase mediated by conventional memory CD4 + and/or CD8 + T cells. Although measurement of vaccine-induced protection 30 days after MTBI is a standard measure of vaccine efficacy in the TB model, this time point might be independent of memory T cells in CC042 mice. Our results suggest that vaccine-elicited innate/innate-like responses could have a larger role in protection than previously considered. The concordance between lung CFU, pathology, and survival makes CC042 mice useful for mechanistic studies on vaccine-induced immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BCG VaccineMycobacterium tuberculosisTuberculosisT-LymphocytesTuberculosis, PulmonaryAnimalsMiceVaccinationImmunity, InnateLungDisease Models, AnimalFemaleCD4-Positive T-LymphocytesImmunologic MemoryCD8-Positive T-Lymphocytes

Stichwörter der Autor:innen

ImmunologyInfectious diseaseInflammationT cellsTuberculosisVaccines

Substanzen

BCG Vaccine

Autor:innen und Institutionen

  • Morningside Graduate School of Biomedical Sciences.
  • Medical Scientist Training Program, and.
  • Department of Microbiology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
  • Texas Biomedical Research Institute, San Antonio, Texas, USA.

Förderung

  • NHLBI NIH HHS
  • NIGMS NIH HHS
  • NIAID NIH HHS
  • NIH HHS
  • NIH/NIAID
  • NIHLBI
  • NIAID
  • NIH

Zitieren

APA

Ogunsola, A. F., Lai, R., Cavallo, K., Tran, A. V., Beamer, G. L., & Behar, S. M. (2026). BCG vaccination elicits protection against M. tuberculosis infection mediated by two phases of T cell immunity. JCI Insight. https://doi.org/10.1172/jci.insight.201000

Vancouver

Ogunsola AF, Lai R, Cavallo K, Tran AV, Beamer GL, Behar SM. BCG vaccination elicits protection against M. tuberculosis infection mediated by two phases of T cell immunity. JCI Insight. 2026. doi:10.1172/jci.insight.201000

BibTeX
@article{Ogunsola2026,
  author = {Ogunsola, Abiola F and Lai, Rocky and Cavallo, Kelly and Tran, Anthony V and Beamer, Gillian L and Behar, Samuel M},
  title = {BCG vaccination elicits protection against M. tuberculosis infection mediated by two phases of T cell immunity},
  journal = {JCI Insight},
  year = {2026},
  doi = {10.1172/jci.insight.201000}
}
Kostenlos starten →